Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
23
datasets available to search
ShareScore release 0.9.0
Dataset results
23 results for “Frontotemporal degeneration”
Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration
Open the record for dataset details and reuse information.
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov study NCT02590276. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
ClinicalTrials.gov study NCT02365922. IPD Sharing: Not stated. Countries: 2. Publications: 11.
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ClinicalTrials.gov study NCT04363684. IPD Sharing: YES. Countries: 2. Publications: 1.
Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration
ClinicalTrials.gov study NCT07316413. IPD Sharing: Not stated. Countries: 1. Publications: 18.
Ex Vivo MRI in Frontotemporal Lobar Degeneration
Open the record for dataset details and reuse information.
Data from: Incidence of frontotemporal lobar degeneration in Italy: the Salento-Brescia Registry study
Objective The goal of the present work, based on a collaborative research registry in Italy (the Salento-Brescia Registry), was to assess the incidence of frontotemporal lobar degeneration (FTLD) and to define the frequencies of different FTLD phenotypes in the general population. Methods The study was conducted from January 1, 2017, to December 31, 2017, in 2 Italian provinces: Lecce (in Puglia) in the south (area 2,799.07 km2, inhabitants 802,082) and Brescia (in Lombardy) in the north (area 4,785.62 km2, inhabitants 1,262,678). During the study period, all new cases of FTLD (incident FTLD) were counted, and all patients' records were reviewed. The incidence was standardized to the Italian general population in 2017. Results In the 2 provinces, 63 patients with FTLD were diagnosed. The incidence rate for FTLD was 3.05 (95% confidence interval [CI] 2.34–3.90) per 100,000 person-years (py), while the age-sex standardized incidence rate was 3.09 (95% CI 2.95–3.23) per 100,000 py. In the Italian population, the lifetime risk was 1:400. There was a progressive increase in FTLD incidence across age groups, reaching its peak in the 75- to 79-year-old group, with an incidence rate of 15.97 (95% CI 8.94–26.33) per 100,000 py. The behavioral variant of frontotemporal dementia was the most common phenotype (37%). No difference in crude incidence rate between the 2 provinces was observed. Conclusion FTLD is a more common form of dementia than previously recognized, with a risk spanning in a wide age range and with maximum incidence in the mid-70s. Improved knowledge of FTLD epidemiology will help to provide appropriate public health service policies.
Supplementary material for: Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease
<p><span><span><span><span><span><span><span><span><span><span><span><b>Objective:</b> <span><span>To<b> </b>test the hypothesis that<b> </b>plasma total tau (t-tau) and neurofilament light chain (NfL) concentrations may have a differential role in the study of frontotemporal lobar degeneration syndromes (FTLD-S) and clinically-diagnosed Alzheimer's disease (AD-S), we determined their diagnostic and prognostic value in FTLD-S and AD-S and their sensitivity to pathological diagnoses.</span></span></span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Methods:</b> We measured plasma t-tau and NfL with the Simoa platform in 265 participants: 167 FTLD-S, 43 AD-S, and 55 healthy controls (HC), including 82 pathology-proven cases (50 FTLD-Tau, 18 FTLD-TDP, 2 FTLD-FUS, and 12 AD) and 98 participants with amyloid PET. We compared cross-sectional and longitudinal biomarker concentrations between groups, their correlation with clinical measures of disease severity, progression and survival and cortical thickness.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Results:</b> Plasma NfL, but not plasma t-tau discriminated FTLD-S from HC and AD-S from HC. Both plasma NfL and t-tau were poor discriminators between FLTD-S and AD-S. In pathology confirmed cases, plasma NfL was higher in FTLD than AD and in FTLD-TDP compared to FTLD-Tau, after accounting for age and disease severity. Plasma NfL, but not plasma t-tau, predicted clinical decline and survival and correlated with regional cortical thickness in both FTLD-S and AD-S. The combination of plasma NfL with plasma t-tau did not outperform plasma NfL alone.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Conclusions:</b> Plasma NfL is superior to plasma t-tau for the diagnosis and prediction of clinical progression of FTLD-S and AD-S.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Classification of Evidence:</b> This study provides Class III evidence that plasma NfL has superior diagnostic and prognostic performance than plasma t-tau in FTLD and AD. </span></span></span></span></span></span></span></span></span></span></span></p>
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
ClinicalTrials.gov study NCT00187525. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Supplementary material for: Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease
Open the record for dataset details and reuse information.
Data from: Incidence of frontotemporal lobar degeneration in Italy: the Salento-Brescia Registry study
Open the record for dataset details and reuse information.
Glial profiling of human tauopathy brain demonstrates enrichment of astrocytic transcripts in tau-related frontotemporal degeneration
GEO Series GSE193391. Homo sapiens. 24 samples. Type: Expression profiling by array.
DAPHNE Scale Validation in Frontotemporal Lobar Degeneration
ClinicalTrials.gov study NCT02889601. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
ClinicalTrials.gov study NCT05956834. IPD Sharing: YES. Countries: 1. Publications: 0.
Multidisciplinary and Personalized Care of Behavioral Disorders in Frontotemporal Lobar Degeneration.
ClinicalTrials.gov study NCT03606798. IPD Sharing: NO. Countries: 1. Publications: 0.
Social Cognition in Ageing and in Frontotemporal Lobar Degeneration
ClinicalTrials.gov study NCT01962064. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials
ClinicalTrials.gov study NCT07110207. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Diagnosing Frontotemporal Lobar Degeneration
ClinicalTrials.gov study NCT02964637. IPD Sharing: NO. Countries: 1. Publications: 0.
Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration
ClinicalTrials.gov study NCT02964611. IPD Sharing: NO. Countries: 1. Publications: 0.
PET Study With 11 C-PIB to Evaluate Amyloid Protein Deposits in Mild Cognitive Disorder, Alzheimer's Disease and Early Frontotemporal Degeneration.
ClinicalTrials.gov study NCT06179979. IPD Sharing: NO. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.